- Home
- TNXP vs KZIA Comparison
TNXP vs KZIA Comparison
Compare TNXP & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- KZIA
- Stock Information
- Founded
- TNXP 2007
- KZIA 1994
- Country
- TNXP United States
- KZIA Australia
- Employees
- TNXP N/A
- KZIA N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- TNXP Health Care
- KZIA Health Care
- Exchange
- TNXP Nasdaq
- KZIA Nasdaq
- Market Cap
- TNXP 15.1M
- KZIA 12.6M
- IPO Year
- TNXP N/A
- KZIA 1999
- Fundamental
- Price
- TNXP $0.14
- KZIA $0.39
- Analyst Decision
- TNXP Strong Buy
- KZIA Strong Buy
- Analyst Count
- TNXP 2
- KZIA 1
- Target Price
- TNXP $53.50
- KZIA $2.00
- AVG Volume (30 Days)
- TNXP 25.2M
- KZIA 529.9K
- Earning Date
- TNXP 11-07-2024
- KZIA 10-22-2024
- Dividend Yield
- TNXP N/A
- KZIA N/A
- EPS Growth
- TNXP N/A
- KZIA N/A
- EPS
- TNXP N/A
- KZIA N/A
- Revenue
- TNXP $12,458,000.00
- KZIA $382.00
- Revenue This Year
- TNXP $62.53
- KZIA $4,053,954.00
- Revenue Next Year
- TNXP $26.17
- KZIA N/A
- P/E Ratio
- TNXP N/A
- KZIA N/A
- Revenue Growth
- TNXP N/A
- KZIA N/A
- 52 Week Low
- TNXP $0.12
- KZIA $0.19
- 52 Week High
- TNXP $22.08
- KZIA $1.58
- Technical
- Relative Strength Index (RSI)
- TNXP 36.97
- KZIA 50.64
- Support Level
- TNXP $0.13
- KZIA $0.38
- Resistance Level
- TNXP $0.18
- KZIA $0.46
- Average True Range (ATR)
- TNXP 0.02
- KZIA 0.03
- MACD
- TNXP 0.01
- KZIA -0.00
- Stochastic Oscillator
- TNXP 33.33
- KZIA 32.35
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.